ESC 23: SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation

Radcliffe
Radcliffe
445 بار بازدید - 12 ماه پیش - Dr Alan Bulava (Ceske Budejovice
Dr Alan Bulava (Ceske Budejovice Hospital and University of South Bohemia, CZ) joins us in this succinct interview to discuss the findings from the SurHyb trial.

The SurHyb study was a prospective, open-label-multicentre randomized trial. The study aimed to evaluate CryoMaze surgery alone, as compared to CryoMaze followed by radiofrequency catheter ablation 3-months post-surgery.

Findings suggest that the incidence of atrial fibrillation and atrial tachycardia was reduced by 62%. The absolute risk reduction was 30%.

Questions:
-What is the reasoning behind this study?
-What was the patient population and study design?
-What are the key findings?
-What are the potential benefits of CryoMaze and Ablation?
-How should these findings impact clinical practice?
-What further study is still required?

Recorded on-site at ESC Congress 2023, Amsterdam.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?...

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: Facebook: RadcliffeCardiology
Follow us on Twitter: Twitter: radcliffeCARDIO
12 ماه پیش در تاریخ 1402/06/05 منتشر شده است.
445 بـار بازدید شده
... بیشتر